Celularity's Strategic Partner Announces Groundbreaking For Stem Cell & Regenerative Medicine Center In Asia Pacific
Celularity's Strategic Partner Announces Groundbreaking For Stem Cell & Regenerative Medicine Center In Asia Pacific
- Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific region
-
Genting Berhad announced groundbreaking on a new, state-of-the-art wellness and health center in Bali, Indonesia, that will utilize Celularity products
-
Strategic partnership positions Celularity to be a key supplier of innovative stem cell and regenerative medicine products for use in the Asia Pacific region
- Celularity正在與其戰略伙伴雲頂集團合作，將Celularity胎盤來源的同種異體幹細胞治療方案引入亞太地區
- 雲頂集團宣佈在印尼巴厘島破土動工建設一座新的最先進的健康與保健中心，該中心將利用Celularity的產品
- 戰略合作使Celularity有望成爲亞太地區創新幹細胞和再生醫學產品的主要供應商
FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad's press release. The new center is expected to commence commercial operations towards the end of 2026.
新澤西州佛羅拉姆公園，2024年11月20日（全球新聞網）-- Celularity Inc.(納斯達克:CELU)（"Celularity"），一家再生和細胞醫學公司，今日宣佈其戰略伙伴雲頂集團已在印尼巴厘島的聖諾特別經濟區破土動工建設Fontaine Vitale，這是一座最先進的幹細胞和再生醫學設施。Fontaine Vitale將提供世界級的細胞治療，專注於健康、美學和再生醫學，面向當地和國際患者，使用由Celularity在其美國設施生產的胎盤來源幹細胞，按照雲頂集團的新聞稿，該中心預計將在2026年底開始商業運營。
譯文內容由第三人軟體翻譯。
